Investigational drug · Phase 2
QL2401
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metabolic Dysfunction-associated Steatohepatitis (MASH).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "QL2401"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QL2401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "QL2401" as an intervention, largest first.
- To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver FibrosisPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07620366 · 132 participants (planned) · Start Dec 2026 · Primary completion Jun 2027
Drug: QL2401 25 mg; QL2401 50 mg and 4 more · For: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Qilu Pharmaceutical Co., Ltd.Industry
NCT07331545 · 71 participants · Start Jan 21, 2026 · Primary completion Jun 24, 2026
Drug: QL2401; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis(MASH)
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metabolic Dysfunction-associated Steatohepatitis (MASH)
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- IBI362Phase 38 trials
Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea
- PemvidutidePhase 34 trials
Altimmune, Inc. · Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD)
- HRS-4729Phase 23 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes, Overweight or Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.